REIG JOFRE has successfully completed the co-development of TRIFERTY-ATM®, a food supplement that contributes to male fertility
REIG JOFRE, pharmaceutical company listed on the Spanish stock exchange, has completed the co-development of TRIFERTY-ATM®, as a result of the collaboration between the research and innovation teams of REIG JOFRE and the Barcelona Center for Male Infertility and Analysis (CIMAB).
TRIFERTY-ATM® is a food supplement that contributes to fertility and reproduction, promotes normal sperm formation, normal energy metabolism and helps reduce cellular oxidative stress.
In Spain, this food supplement will be distributed with the commercial support of Fertil Ibérica, a spin-off of the Universitat Autònoma de Barcelona, promoted by CIMAB researchers, with the aim of bringing the most innovative technologies in the field of male fertility to fertility centers and patients. Likewise, its international launch is planned through the REIG JOFRE subsidiary in Sweden, and by distribution agreements in Jordan and Vietnam, during 2023.
This co-development is part of the company’s collaborative innovation strategy, as a lever for the development of new products with advanced solutions at the service of patients and health care.
REIG JOFRE, dedicated to the research, development, manufacture and marketing of pharmaceutical products and food supplements, structures its activity into three business units: Pharmaceutical Technologies (sterile injectables, lyophilized products and antibiotics), Specialty Pharmacare (dermatology, osteoarticular, health of the women and pediatrics) and Consumer Healthcare (food supplements and OTC products). Founded in 1929 in Barcelona (Spain), REIG JOFRE has more than 1,100 employees, 4 development and production centers in Europe, subsidiaries in 8 countries (Spain, France, Portugal, Belgium, Sweden, United Kingdom, Poland, and Singapore) and 155 commercial partners in more than 70 countries. In 2021, the company’s turnover was €236 million